Screening and prevention of gestational hypertension and preeclampsia
The Project of Gestational Hypertension and Preeclampsia Screening and Prevention
The Third Affiliated Hospital of Guangzhou Medical University · NCT06383858
This study is testing a new way to identify and manage pregnant women at high risk for preeclampsia to help prevent complications for both mothers and babies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50000 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | The Third Affiliated Hospital of Guangzhou Medical University (other) |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06383858 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate a preeclampsia risk screening scheme based on maternal high-risk factors and placental growth factor (PlGF) detection. It focuses on early prediction and targeted management of high-risk pregnant women to reduce the incidence of preeclampsia and associated complications. By establishing appropriate screening and prevention standards for the Chinese population, the study seeks to significantly lower maternal and fetal mortality rates. The methodology involves real-world assessments and interventions to improve outcomes for pregnant women.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women who have been screened for preeclampsia risk based on clinical guidelines.
Not a fit: Patients with severe fetal malformations or those who have been using aspirin regularly prior to joining the study may not benefit.
Why it matters
Potential benefit: If successful, this study could lead to a significant reduction in maternal and fetal deaths associated with preeclampsia.
How similar studies have performed: Other studies have shown success with similar screening approaches, indicating potential for effective intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\) Pregnant women who have been screened for pre-eclampsia risk according to the clinical risk factors listed in NICE guidelines (2019); * 2\) Based on the authoritative guideline of Figo and the consensus of experts in China, pregnant women who routinely use maternal factor +MAP＋PLGF±UtA-PI in the first trimester or PLGF or sFlt-1/PLGF in the second and third trimesters to assess the risk of preeclampsia. * 3\) Meet any of the above conditions, join the group voluntarily, and sign the informed consent form. Exclusion Criteria: * 1\) Severe fetal malformation or abnormality (no fetal heartbeat); * 2\) Those who regularly use aspirin before joining the group; * 3\) There are obvious other abnormal signs, laboratory tests or other clinical d• iseases, which are judged by the researcher to be not suitable for participating in researchers; * 4\) Unable to obtain follow-up and delivery information.
Where this trial is running
Guangzhou, Guangdong
- FANG HE — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Principal investigator: Dunjin Chen, Professor — The Third Affiliated Hospital of Guangzhou Medical University
- Study coordinator: Dunjin Chen, Professor
- Email: gzdrchen@gzhmu.edu.cn
- Phone: 18928916722
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Preeclampsia, Maternal Deaths, Placental growth factor, Real-World Study, Screening, Prevention